Autoimmune Encephalitis surgery
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Julinka Auta Fernandes
|
Autoimmune Encephalitis Microchapters |
|
Differentiating Autoimmune Encephalitis from Other Conditions |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Autoimmune Encephalitis On the Web |
Overview
Autoimmune encephalitis is primarily treated medically, but removal of an associated tumor can be an important component of treatment. Surgery is directed at the relevant neoplasm or a specific complication, rather than routine removal of brain tissue.[1]
Surgery
Resection of an Associated Tumor
Autoimmune encephalitis associated with a relevant, resectable neoplasm warrants prompt surgical and oncological assessment. Tumor treatment should proceed alongside immunotherapy when feasible. The operation depends on tumor location, histology, stage, and patient stability; not every associated malignancy is treated surgically.[2]
Ovarian Teratoma Resection
Autoimmune encephalitis associated with N-methyl-D-aspartate receptor (NMDAR) antibodies and an ovarian teratoma requires gynecological assessment for tumor removal. Where oncologically appropriate, favor an approach that removes the lesion while preserving ovarian function and fertility. The extent of surgery should reflect lesion characteristics rather than encephalitis severity alone.[3]
Autoimmune encephalitis does not necessarily resolve immediately after tumor removal. Continue neurological treatment and rehabilitation according to clinical response.[4]
Imaging-Negative Disease and Oophorectomy
Autoimmune encephalitis with negative ovarian imaging does not routinely justify empirical bilateral oophorectomy. The Canadian consensus describes this as controversial, with weak evidence and irreversible fertility and endocrine consequences. Some guideline authors oppose offering it at all. Any exceptional consideration requires specialist multidisciplinary review of persistently life-threatening disease despite second- and third-line treatment, repeated multimodal pelvic imaging, cerebrospinal fluid confirmation of NMDAR antibodies, and legally valid informed consent. It is not recommended by that consensus outside ages 18–45.[2]
Autoimmune encephalitis surgical evidence remains limited: a small retrospective comparison found no demonstrated functional advantage from aggressive ovarian resection. Its observational design and differences between patient groups preclude definitive causal conclusions. The authors favored function-preserving surgery for an imaging-confirmed or suspected teratoma and repeated imaging when initial investigations were negative.[3]
Brain Biopsy
Autoimmune encephalitis generally does not require brain biopsy when the presentation and investigations are typical. Targeted biopsy may be considered for atypical or mass-like lesions when an alternative diagnosis, such as malignancy, remains unresolved. Histological findings can be nonspecific; biopsy is not a routine confirmatory test for autoimmune encephalitis.[1]
Procedures for Complications
Autoimmune encephalitis with prolonged respiratory or feeding impairment may require tracheostomy or gastrostomy. These procedures support care rather than treat the underlying immune process. Decisions should reflect the anticipated course and multidisciplinary assessment.[5]
See interventions.
Indications
Autoimmune encephalitis-related indications for surgical assessment include:
- A relevant neoplasm for which resection is appropriate.
- An unresolved atypical brain lesion requiring tissue diagnosis.
- Prolonged airway or nutritional support needs requiring a procedure.[2][1][5]
Contraindications and Limitations
Autoimmune encephalitis has no single procedure-independent list of surgical contraindications. Assess anesthetic risk, respiratory compromise, dysautonomia, infection, bleeding risk, and the proposed operation's expected benefit. Severe neurological impairment alone should not automatically exclude potentially beneficial tumor treatment.[1][4]
Autoimmune encephalitis without an identified surgical target is not an indication for routine exploratory surgery or removal of normal ovaries.[3]
Pediatric Considerations
Autoimmune encephalitis in children requires pediatric neurology and appropriate surgical expertise. The pediatric NMDAR consensus emphasizes early tumor investigation and timely removal when a tumor is identified. Negative initial imaging may require reassessment, especially with poor response or relapse; it does not establish a need for empirical ovarian removal.[4]
Postoperative Care
Autoimmune encephalitis requires continued immunotherapy assessment, seizure and autonomic monitoring, rehabilitation, and tumor-specific follow-up after surgery. Review histopathology and coordinate subsequent care with the relevant surgical and oncology teams.[2][5]
See medical therapy, symptomatic and supportive therapy, and screening for an associated neoplasm.
References
- ↑ 1.0 1.1 1.2 1.3 Abboud H, Probasco JC, Irani S, et al. Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management. J Neurol Neurosurg Psychiatry. 2021;92(7):757–768. doi:10.1136/jnnp-2020-325300. PMID:33649022.
- ↑ 2.0 2.1 2.2 2.3 Hahn C, Budhram A, Alikhani K, et al. Canadian Consensus Guidelines for the Diagnosis and Treatment of Autoimmune Encephalitis in Adults. Can J Neurol Sci. 2024;51(6):734–754. doi:10.1017/cjn.2024.16. PMID:38312020.
- ↑ 3.0 3.1 3.2 Iyengar Y, Hébert J, Climans SA, et al. Ovarian resection in anti-N-methyl-D-aspartate receptor encephalitis: A comparison of surgical approaches. Front Neurol. 2022;13:1043785. doi:10.3389/fneur.2022.1043785. PMID:36468045.
- ↑ 4.0 4.1 4.2 Nosadini M, Thomas T, Eyre M, et al. International Consensus Recommendations for the Treatment of Pediatric NMDAR Antibody Encephalitis. Neurol Neuroimmunol Neuroinflamm. 2021;8(5):e1052. doi:10.1212/NXI.0000000000001052. PMID:34301820.
- ↑ 5.0 5.1 5.2 Abboud H, Probasco J, Irani SR, et al. Autoimmune encephalitis: proposed recommendations for symptomatic and long-term management. J Neurol Neurosurg Psychiatry. 2021;92(8):897–907. doi:10.1136/jnnp-2020-325302. PMID:33649021.